Shanghai Henlius Biotech Yönetim

Yönetim kriter kontrolleri 2/4

Shanghai Henlius Biotech CEO'su Jason Zhu, Jul2023 tarihinde atandı, in görev süresi 1.58 yıldır. in toplam yıllık tazminatı CN¥ 9.26M olup, şirket hissesi ve opsiyonları dahil olmak üzere 87.8% maaş ve 12.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.009% ine doğrudan sahiptir ve bu hisseler HK$ 1.05M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.1 yıl ve 5.4 yıldır.

Anahtar bilgiler

Jason Zhu

İcra Kurulu Başkanı

CN¥9.3m

Toplam tazminat

CEO maaş yüzdesi	87.8%
CEO görev süresi	1.6yrs
CEO sahipliği	0.009%
Yönetim ortalama görev süresi	2.1yrs
Yönetim Kurulu ortalama görev süresi	5.4yrs

Son yönetim güncellemeleri

Recent updates

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

May 25

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Mar 25

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Mar 10

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Dec 31

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Nov 25

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Sep 18

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Aug 03

Shanghai Henlius Biotech (HKG:2696) Has Debt But No Earnings; Should You Worry?

May 31

Need To Know: Analysts Are Much More Bullish On Shanghai Henlius Biotech, Inc. (HKG:2696) Revenues

Apr 06

CEO Tazminat Analizi

Jason Zhu'un ücretlendirmesi Shanghai Henlius Biotech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	CN¥692m
Mar 31 2024	n/a	n/a	CN¥619m
Dec 31 2023	CN¥9m	CN¥8m	CN¥546m

Tazminat ve Piyasa: Jason 'nin toplam tazminatı ($USD 1.28M ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 514.88K ).

Tazminat ve Kazançlar: Jason şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Jason Zhu (46 yo)

1.6yrs

Görev süresi

CN¥9,261,000

Tazminat

Dr. Jun Zhu, also known as Jason, had been Chief Financial Officer at Shanghai Henlius Biotech, Inc. since May 1, 2023 until July 1, 2024 and served as its President since November 30, 2021 until October 1...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Wenjie Zhang	Executive Chairman of the Board	5.1yrs	CN¥12.58m	Veri yok
Jun Zhu	CEO & Executive Director	1.6yrs	CN¥9.26m	0.0092% HK$ 1.1m
Huang Wei	President	1.3yrs	Veri yok	Veri yok
Shi-Kau Liu	Co-founder & Head of Strategy Advisory Committee	15yrs	CN¥6.21m	0.44% HK$ 50.7m
Wei-Dong Jiang	Co-Founder & Co-Head of Innovative Advisory Committee	15yrs	Veri yok	0.13% HK$ 15.2m
Yingbo Mao	VP & CFO	less than a year	Veri yok	Veri yok
Jifeng Zhang	CTO & Senior VP	2.2yrs	Veri yok	Veri yok
Jijun Yuan	Chief Scientific Officer	1.1yrs	Veri yok	Veri yok
Miaojie Chen	Vice President of Legal & Compliance Department	2.1yrs	Veri yok	Veri yok
Yan Wang	Deputy GM of Public Relations & Joint Company Secretary	3.3yrs	Veri yok	Veri yok
Wallis Zeng	VP of Sales & Oncology Business Unit	5.1yrs	Veri yok	Veri yok
Junhua Li	VP & Chief Human Resource Officer	2.8yrs	Veri yok	Veri yok

2.1yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: 2696 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Wenjie Zhang	Executive Chairman of the Board	5.1yrs	CN¥12.58m	Veri yok
Jun Zhu	CEO & Executive Director	1.5yrs	CN¥9.26m	0.0092% HK$ 1.1m
Tak Young So	Independent Non-Executive Director	5.4yrs	CN¥258.00k	Veri yok
Qiyu Chen	Non-Executive Director	12.1yrs	Veri yok	Veri yok
Guoping Zhao	Independent Non-Executive Director	5.4yrs	CN¥258.00k	Veri yok
Xiaohui Guan	Non-Executive Director	6.2yrs	Veri yok	Veri yok
K. Christopher Garcia	Member of Scientific Advisory Board	1.6yrs	Veri yok	Veri yok
Yifang Wu	Non-Executive Director	9.7yrs	Veri yok	Veri yok
Deyong Wen	Non-Executive Director	2.6yrs	Veri yok	Veri yok
Lik Yuen Chan	Independent Non-Executive Director	5.4yrs	CN¥258.00k	Veri yok
Ruilin Song	Independent Non-Executive Director	5.4yrs	CN¥258.00k	Veri yok
Rongli Feng	Chairman of Supervisory Board	4.8yrs	Veri yok	Veri yok

5.4yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 2696 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/15 14:23
Gün Sonu Hisse Fiyatı	2025/02/14 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Shanghai Henlius Biotech, Inc. 14 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Yang Huang	BofA Global Research
Wangbin Zhou	Citigroup Inc
Eva Zhao	Citigroup Inc

Shanghai Henlius Biotech Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shanghai Henlius Biotech, Inc. Announces Company Secretary Changes

Shanghai Henlius Biotech, Inc. Announces Chief Financial Officer Changes

Less than half of directors are independent

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

Recent updates

Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 2 Clinical Study of HLX43 for Injection

Investor sentiment improves as stock rises 20%

Shanghai Henlius Biotech, Inc. Announces Biologics License Application Forpertuzumab Biosimilar Hlx11(Recombinant Anti-Her2 Domain II Humanizedmonoclonal Antibody Injection) Accepted by the United States Food and Drug Administration

Investor sentiment deteriorates as stock falls 17%

Shanghai Henlius Biotech, Inc. Announces Approval of Application for Phase 1B/2 Clinical Trial of Hlx43 for Injection (Antibody-Drug Conjugate Targetingpd-L1 with Novel Dna Topoisomerase I Inhibitor) in Combination with Hansizhuang (Serplulimab Injection)

Shanghai Henlius Biotech, Inc. Announces First Patient in Mainland China Dosed in an International Multi-Center Phase 3 Clinical Study

New major risk - Revenue and earnings growth

Shanghai Henlius Biotech Announces Application for the Phase 1b/2 Clinical Trial of HLX43 for Injection Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces New Drug Application for New Indication of Hansizhuang (Serplulimab Injection)

Shanghai Henlius Biotech, Inc. Announces First Patient Has Been Dosed in an International Multi-Center Phase 3 Clinical Study of HLX22

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Shanghai Henlius Biotech, Inc. Announces First Patient in Japan Dosed in an International Multicentre Phase 3 Clinical Study of Hansizhuang (Serplulimab Injection) in Combination with Bevacizumab Injection and Chemotherapy for the First-Line Treatment of Metastatic Colorectal Cancer (mCRC)

Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11

First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023)

Shanghai Henlius Biotech, Inc. Receives Positive Opinion from the Committee Formedicinal Products for Human Use (Chmp)Of the European Medicines Agency (Ema)

Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of Pembrolizumab Biosimilar HLX17 (Recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection)

First half 2024 earnings released: EPS: CN¥0.71 (vs CN¥0.44 in 1H 2023)

Shanghai Henlius Biotech, Inc. Announces Company Secretary Changes

Shanghai Henlius Biotech, Inc. to Report First Half, 2024 Results on Aug 26, 2024

Shanghai Henlius Biotech, Inc. Announces the First Patient Dose in A Phase 2 Clinical Trial of HLX53

Shanghai Henlius Biotech, Inc. Announces International Multicentre Phase 3 Clinical Trial for the First-Line Treatment of Metastatic Colorectal Cancer in Japan

Shanghai Henlius Biotech, Inc. Announces Chief Financial Officer Changes

Shanghai Henlius Biotech, Inc. Announces Completion of Phase 1 Clinical Study of a Biosimilar of Daratumumab HLX15 (Recombinant Anti-CD38 Human Monoclonal Antibody

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) agreed to acquire 78.3% stake in Shanghai Henlius Biotech, Inc. (SEHK:2696) from a group of shareholders for CNY 4.3 billion.

Investor sentiment improves as stock rises 19%

Less than half of directors are independent

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14

National Medical Products Administration Approves Shanghai Henlius Biotech, Inc.'S the Supplemental Applications of Handayuan (Adalimumab Injection) for the New Indications

Shanghai Henlius Biotech, Inc. Announces Approval of Application for Clinical Trials of HLX78 (lasofoxifene) by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Application for the Phase 3 Clinical Trial of HLX22 in Combination with Trastuzumab and Chemotherapy as the First-Line Treatment of HER2 Positive Advanced Gastric Cancer Approved by the United States Food and Drug Administration (FDA)

Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China

Shanghai Henlius Biotech, Inc., Annual General Meeting, May 20, 2024

Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints

Shanghai Henlius Biotech, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc.'s (HKG:2696) Price Is Right But Growth Is Lacking

Shanghai Henlius Biotech, Inc. Announces Supplemental New Drug Applications of HANDAYUAN (Adalimumab Injection) for the New Indications Have Been Accepted by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Phase 1 Clinical Study of A Biosimilar of Denosumab HLX14 Successfully Completed

Here's Why Shanghai Henlius Biotech (HKG:2696) Is Weighed Down By Its Debt Load

Shanghai Henlius Biotech, Inc. Receives Fast Track Designation by the United States Food and Drug Administration

New major risk - Financial position

Shanghai Henlius Biotech, Inc. Announces Dosing of First Subject in A Phase 1 Clinical Studyin Healthy Chinese Male Subjects of Ipilimumab Biosimilarhlx13 (Recombinant Anti-Ctla-4 Fully Human Monoclonalantibody Injection)

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

Shanghai Henlius Biotech, Inc. Announces Application for Phase 1 Clinical Trial of Hlx43 for Injection

The Strong Earnings Posted By Shanghai Henlius Biotech (HKG:2696) Are A Good Indication Of The Strength Of The Business

Shanghai Henlius Biotech, Inc. Receives Approval from United States Food and Drug Administration for Application for Phase 1 Clinical Trial of HLX42 for Injection (Antibody-Drug Conjugate Targeting EGFR with Novel DNA Topoisomerase I Inhibitor)

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13

New minor risk - Financial position

Shanghai Henlius Biotech, Inc. to Report Nine Months, 2023 Results on Nov 15, 2023

Shanghai Henlius Biotech, Inc. Announces Shenzhen Nansiuzhuiang in Combination with Chemotherapy for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Shanghai Henlius Biotech, Inc. Announces NMPA Approvals of Two ADC Candidates for IND

Shanghai Henlius Biotech, Inc. Announces the First Patient in Europe Has Been Dosed in the International Multi-Centre Phase 3 Clinical Trial

Shanghai Henlius Biotech, Inc. Appoints Wei Huang as President

Shanghai Henlius Biotech, Inc. Announces the New Drug Application (Nda) for New Indication of Hansizhuang (Serplulimab Injection) an Innovative Anti-PD-1 Monoclonal Antibody

Is Shanghai Henlius Biotech (HKG:2696) Using Too Much Debt?

Shanghai Henlius Biotech, Inc. Announces Executive Appointments

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.47 loss in 1H 2022)

Shanghai Henlius Biotech, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Improved Revenues Required Before Shanghai Henlius Biotech, Inc. (HKG:2696) Shares Find Their Feet

Forecast breakeven date moved forward to 2023

Shanghai Henlius Biotech, Inc. Announces Resignation of Zihou Yan as Non-Executive Director, Member of the Strategy Committee and Environmental, Social and Governance Committee

Consensus EPS estimates fall by 31%

Shanghai Henlius Biotech, Inc. Provides Unaudited Consolidated Financial Guidance for the Six Months Ended 30 June 2023

Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of Ipilimumab Biosimilar HLX13 (Recombinant Anti-CTLA-4 Fully Human Monoclonal Antibody Injection) Approved by the National Medical Products Administration

Shanghai Henlius Biotech, Inc. Announces Dosing of First Patient in a Phase 2 Clinical Trial of HLX26